Accueil   Diary - News   All news Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models

 

 

 

  • genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models

 

  • New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients

 

Darmstadt, Germany, December 10, 2018 – Merck, a leading science and technology company and leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree